Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
'This SPA model serves to take advantage of the deep expertise of each individual site and ensure that protocols and best practices are shared consistently,' said Doug Drysdale, Chief Executive Officer of Cybin. 'This level of cooperation will streamline trial operations and has the potential to reduce time to completion. We are especially pleased that Kimball A. Johnson, M.D., Medical Director of CenExel iResearch Atlanta, who served as the principal investigator for our successful Phase 1/2a CYB003 trial, and Paul Thielking, Chief Scientific Officer, Cedar Clinical Research, are participating in the SPA program. Our SPA partners are experienced in neuropsychiatric drug trials and share Cybin's deep commitment to the highest quality standards of investigational clinical work, and to developing safe and effective next-generation treatments to improve patient outcomes.'
'I am delighted that iResearch Atlanta is participating in this next exciting stage of development for CYB003, and that we will be part of a consortium of sites working to advance its Phase 3 program,' said Kimball A. Johnson, M.D., Medical Director of CenExel iResearch Atlanta.
'Cedar Clinical Research has extensive experience in this space, and we are eager to join the other sites supporting Cybin's PARADIGM program and address the global crisis in mental health,' said Paul Thielking, Chief Scientific Officer, Cedar Clinical Research, a Numinus Wellness Inc. company.
Cybin initiated the SPA program earlier this year with Segal Trials, a leading clinical research network located in South Florida. Each of the 18 U.S.-based SPA sites bring decades of clinical experience and a commitment to excellence to support and expedite the Company's Phase 3 PARADIGM program.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll patients across clinical sites in the United States and Europe; the potential reduction in drug development timeline afforded by its SPA program; the eventual inclusion of approximately 45 clinical sites; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
21 minutes ago
- TechCrunch
Why Paradigm built a spreadsheet with an AI agent in every cell
Anna Monaco has been building AI agents since before the term 'AI agents' was even a thing. After building numerous chatbots, she started looking for other types of interfaces that made sense for AI agents and landed on spreadsheets. 'I had this personal pattern, and I noticed that a lot of other people had this pattern, of putting very important CRM data in spreadsheets just because it was the most flexible thing,' Monaco told TechCrunch. 'But it was actually a pain to maintain. There's so much manual work involved. So [I] just went down this rabbit hole of building a product for myself and wanted to reimagine what a spreadsheet could look like with the full power of LLMs.' The result was Paradigm, an AI-powered spreadsheet equipped with more than 5,000 AI agents. Users can assign different prompts to individual columns and cells, and individual AI agents will crawl the internet to find and fill out the needed information. Paradigm works with AI models from Anthropic, OpenAI, and Google's Gemini, Monaco said, and supports model switching. 'We want to support every single model because we want our users to be able to have the highest reasoning outputs when they need it, but also the cheapest outputs,' Monaco said. 'It's just a constant cycle of evaluating different models, working closely with model providers to make sure our limits are high enough, and then giving some of that power to our users.' The company launched a small closed beta preview in late 2024 and has been iterating on the product using customer feedback. Paradigm attracts users ranging from consultants to sales professionals and finance folks and operates on a subscription model with tiers based on usage. Paradigm counts the consulting firm EY, AI chip startup Etched and the AI coding company Cognition as early customers. Paradigm is now releasing its product to the public and announcing that it raised a $5 million seed round led by General Catalyst. The company has raised $7 million to date. Monaco said the funding will go toward executing on the company's 'extremely aggressive product roadmap.' Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW 'The interesting thing that happened when we fundraised is some people we pitched just kept on using and paying for the product,' Monaco said. 'I think that was a cool part of it. We found a lot of value from it internally and our investors, not even just our investors — other investors that we talked to — are still using it.' Paradigm isn't the only company looking to give spreadsheets an AI upgrade. Quadratic, which has raised more than $6 million in venture funding, is a three-year-old startup with a similar goal. Legacy companies like Google and Microsoft are also adding AI tools to their spreadsheet applications. Monaco said that she doesn't really consider the competition because Paradigm doesn't think of itself as an AI-powered spreadsheet. She said she thinks of it as a new AI-powered workflow that happens to be in the familiar form of a spreadsheet but won't necessarily stay that way forever. 'What I'm seeing in the most popular AI products now is this fine balance between present and future,' Monaco said. 'How do you build something that is really powerful and generates a lot of value now but also sets you up really well for the future? That's the question that I asked myself a year ago when I was starting the company.'
Business Wire
4 hours ago
- Business Wire
The Cannabist Company Announces Closing on Sale of Affiliate; Repositioning to a Wholesale Strategy in Pennsylvania
NEW YORK--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) ('The Cannabist Company' or the 'Company'), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today the successful closing of the sale of its Pennsylvania affiliate that owns 3 medical dispensaries ('Pennsylvania Transaction') to VP Investment Holdings, LLC ('VP Holdings'). VP Holdings is comprised of principals from a leading privately-held dispensary operator in Pennsylvania, Restore Integrative Wellness Center, LLC. The sale will include a concurrent supply agreement with VP Holdings for products produced by Cannabist's grow/processing affiliate, Green Leaf Medicals, LLC ('gLeaf'). This strategic Pennsylvania Transaction accelerates The Cannabist Company's wholesale cultivation presence by enhancing the commercialization of its state-of-the-art grow-processor facility located in Saxton, Pennsylvania, while continuing to serve the broader medical market through high-quality medical marijuana. Pennsylvania Transaction Highlights VP Holdings acquired Columbia Care Pennsylvania LLC, from Columbia Care LLC via Equity Purchase Agreement for approximately $10 million in cash paid at closing. Columbia Care Pennsylvania's 3 operational medical dispensaries are located in Scranton, Allentown and Wilkes-Barre, Pennsylvania. VP Holdings expects to rebrand all 3 locations to the Restore brand immediately. As additional consideration, VP Holdings and Restore have entered into a supply agreement with The Cannabist Company (through gLeaf), thereby expanding The Cannabist Company's wholesale distribution footprint in Pennsylvania. The Cannabist Company will continue to enhance and expand its wholesale presence in-state by driving the performance of its Saxton grow-processor facility. The Cannabist Company Management Commentary 'This Pennsylvania Transaction is a clear example of executing on our strategic plan to simplify our business and optimize existing assets, while delivering immediate financial benefits,' stated David Hart, CEO of The Cannabist Company. 'We've taken a proactive and thoughtful step that strengthens our balance sheet, bolsters liquidity, and enhances our operational focus. By divesting our retail footprint in Pennsylvania for all cash and entering into a meaningful wholesale agreement, we are now better positioned to optimize our best-in-class Saxton cultivation facility and expand distribution of our high-quality products to patients across the state. This transaction positions us to better capitalize on the current medical landscape and future opportunities in a potential adult-use market.' CLD Advisory served as exclusive financial advisor and Foley Hoag LLP served as legal advisor, while Cannabis Law Solutions served as Pennsylvania regulatory counsel to The Cannabist Company. Ballard Spahr LLP acted as legal advisor to Restore. About The Cannabist Company (f/k/a Columbia Care) The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 12 U.S. jurisdictions. The Company operates 77 facilities including 61 dispensaries and 16 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit Caution Concerning Forward-Looking Statements This press release contains certain statements that constitute 'forward-looking information' or 'forward-looking statements' within the meaning of applicable securities laws and reflect the Company's current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company's ability to execute on the Pennsylvania Transaction and on its repositioning to a wholesale strategy in Pennsylvania. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. In addition, security holders should review the risk factors discussed under 'Risk Factors' in Columbia Care's Form 10-K for the year ended December 31, 2024, as filed with Canadian and U.S. securities regulatory authorities and described from time to time in subsequent documents filed with applicable securities regulatory authorities.
Associated Press
3 days ago
- Associated Press
Canadian Investment Regulatory Organization Trading Halt - VERS.WT.A
TORONTO, Aug. 15, 2025 /CNW/ - The following issues have been halted by CIRO: Company: Verses AI Inc. Cboe CA Exchange Symbol : All Issues: No Reason: Pending Delisting Halt Time (ET): 12:00 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions
